{"filing":{"accession_number":"0001703057-26-000037","cik":"0001703057","ticker":"ABCL","company_name":"AbCellera Biologics Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"abcl-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/abcl-20260630.htm"},"events":[{"id":17123,"run_id":15328,"accession_number":"0001703057-26-000037","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Lynn Seely, M.D. as a new Class III director to AbCellera's Board of Directors effective June 30, 2026. The principal disclosed action is a person taking a governance role. Dr. Seely is an independent director with substantial biopharmaceutical executive experience, including CEO roles at Lyell Immunopharma and Myovant Sciences, and prior board service at Blueprint Medicines (acquired for $9.1 billion). This is a material governance event affecting the composition and expertise of the board.","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15454,"accession_number":"0001703057-26-000037","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Lynn Seely, M.D. as a new Class III director to AbCellera's Board of Directors effective June 30, 2026. The principal disclosed action is a person taking a governance role. Dr. Seely is an independent director with substantial biopharmaceutical executive experience, including CEO roles at Lyell Immunopharma and Myovant Sciences, and prior board service at Blueprint Medicines (acquired for $9.1 billion). This is a material governance event affecting the composition and expertise of the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:53:51.181963+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15454,"accession_number":"0001703057-26-000037","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Lynn Seely, M.D. as a new Class III director to AbCellera's Board of Directors effective June 30, 2026. The principal disclosed action is a person taking a governance role. Dr. Seely is an independent director with substantial biopharmaceutical executive experience, including CEO roles at Lyell Immunopharma and Myovant Sciences, and prior board service at Blueprint Medicines (acquired for $9.1 billion). This is a material governance event affecting the composition and expertise of the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:53:51.181963+00:00","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-07-06"}]}